You are here

Journal of clinical oncology : official journal of the American Society of Clinical Oncology DOI:10.1200/JCO.2010.28.5148

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Publication TypeJournal Article
Year of Publication2011
AuthorsCho, YJ, Tsherniak, A, Tamayo, P, Santagata, S, Ligon, A, Greulich, H, Berhoukim, R, Amani, V, Goumnerova, L, Eberhart, CG, Lau, CC, Olson, JM, Gilbertson, RJ, Gajjar, A, Delattre, O, Kool, M, Ligon, K, Meyerson, M, Mesirov, JP, Pomeroy, SL
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume29
Issue11
Pages1424-30
Date Published2011/04/10
ISSN0732-183X
Abstract

Medulloblastomas are heterogeneous tumors that collectively represent the most common malignant brain tumor in children. To understand the molecular characteristics underlying their heterogeneity and to identify whether such characteristics represent risk factors for patients with this disease, we performed an integrated genomic analysis of a large series of primary tumors.

URLhttp://www.jco.org/cgi/pmidlookup?view=long&pmid=21098324
DOI10.1200/JCO.2010.28.5148
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/21098324?dopt=Abstract